-
1 Comment
Cassava Sciences, Inc is currently in a long term uptrend where the price is trading 192.9% above its 200 day moving average.
From a valuation standpoint, the stock is 100.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.0.
Cassava Sciences, Inc's total revenue sank by nan% to $0 since the same quarter in the previous year.
Its net income has dropped by 72.7% to $-3M since the same quarter in the previous year.
Finally, its free cash flow fell by 99.5% to $-1M since the same quarter in the previous year.
Based on the above factors, Cassava Sciences, Inc gets an overall score of 2/5.
| Exchange | F |
|---|---|
| CurrencyCode | EUR |
| ISIN | US14817C1071 |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | 80M |
|---|---|
| Beta | -1.48 |
| PE Ratio | None |
| Target Price | 159.25 |
| Dividend Yield | None |
Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2 clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. Cassava Sciences, Inc. was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. The company was incorporated in 1998 and is based in Austin, Texas.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for PX91.F using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025
